{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:04:55Z","timestamp":1794027895159,"version":"4.8.0"},"reference-count":75,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anticipated increase in the prevalence and incidence of type 2 diabetes in Asia, and its associated cardiovascular\u2013renal complications, will place a significant burden on patients, caregivers, and society. Despite the proven effectiveness of lipid management in reducing these complications, there are major treatment gaps, especially in Asian patients with young\u2010onset diabetes and chronic kidney disease (CKD). Recent international guidelines recommended the adoption of absolute risk estimation of atherosclerosis and cardiovascular disease to guide treatment intensity. These recommendations replaced the previous strategy of using low\u2010density lipoprotein cholesterol targets to guide initiation and intensification of lipid lowering, albeit still widely practiced in Asia. The latest guidelines also highlight the high risk of atherosclerosis and cardiovascular disease (ASCVD) for people with diabetes, who should be protected with statins, except for young patients without other risk factors, who will need yearly monitoring of blood lipid levels. Given the propensity of Asian patients with diabetes to develop CKD and the amplifying effect of CKD on ASCVD, the use of statins in Asian patients is particularly important. Due to interethnic differences in drug metabolism, rosuvastatin, which is largely cleared by the kidney, should be prescribed in low dosages (5\u201310 mg daily) in Asian populations. Conversely, epidemiological and experimental data confirm pleotropic and organ\u2010protective effects of atorvastatin, with proven safety in Asian populations within a daily dose range of 10\u201340 mg. Thus, there is a need for Asian countries to review and align their lipid\u2010lowering treatment guidelines to reduce the substantial burden of diabetes in the Asian region.<\/jats:p>","DOI":"10.1111\/1753-0407.12610","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T16:03:46Z","timestamp":1506614626000},"page":"200-212","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction"],"prefix":"10.1111","volume":"10","author":[{"given":"Titus WL","family":"Lau","sequence":"first","affiliation":[{"name":"Division of Nephrology National University Health System, National University Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.K.","family":"Tan","sequence":"additional","affiliation":[{"name":"Mount Elizabeth Medical Centre  Singapore"},{"name":"Mt Alvernia Medical Centre Block A  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.J.","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine Singapore General Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsun\u2010Gun","family":"Ng","sequence":"additional","affiliation":[{"name":"TG Ng Kidney &amp; Medical Centre, Gleneagles Medical Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Tavintharan","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Khoo Teck Puat Hospital  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1194","authenticated-orcid":false,"given":"Juliana C.N.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics and Hong Kong Institute of Diabetes and Obesity The Chinese University of Hong Kong, Prince of Wales Hospital  Shatin Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1536"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr540"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70137-8"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1336"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2013.12.001"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000188034.76283.5e"},{"key":"e_1_2_13_10_1","unstructured":"National Registry of Diabetes Office.Information Paper on Diabetes in Singapore. 2011. Available from:https:\/\/www.nrdo.gov.sg\/docs\/librariesprovider3\/Publications---Kidney-Failure\/info_paper_diabetes_2011nov.pdf(accessed October 2017)."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.2.434"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69292-1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1307"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2661"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021778"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1908"},{"key":"e_1_2_13_23_1","first-page":"S1","article-title":"Standards of medical Care in Diabetes 2016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12188"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.10.019"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02180311"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0971"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4356"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"e_1_2_13_35_1","unstructured":"Clinical Practice Guidelines.Lipids. Singapore Ministry of Health Clinical Practice Guidelines. 2.2016. Available from:https:\/\/www.moh.gov.sg\/content\/dam\/moh_web\/HPP\/Doctors\/cpg_medical\/current\/2016\/lipids\/MOH%20Lipids%20CPG%20\u2010%20Booklet.pdf(accessed 15 August 2017)."},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2015.4.1.61"},{"key":"e_1_2_13_38_1","unstructured":"Malaysian Ministry of Health.4th Edition of Clinical Practice Guidelines. Management of Dyslipidemia.2011. Available from:https:\/\/www.malaysianheart.org\/files\/17706572750124a3988f0c.pdf(accessed 1 October 2017)."},{"key":"e_1_2_13_39_1","unstructured":"Hong Kong Department of Health.Module 8: Lipid Management in Diabetic Patients. Available from:http:\/\/www.pco.gov.hk\/english\/resource\/files\/professionals_DM_Module8.pdf(accessed 1 March 2017)."},{"key":"e_1_2_13_40_1","first-page":"833","article-title":"Chinese guideline for the management of dyslipidemia in adults","volume":"44","author":"Joint Committee issued Chinese Guideline for the Management of Dyslipidemia in Adults","year":"2016","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.11.013"},{"key":"e_1_2_13_42_1","unstructured":"2016 RCPT Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for ASCVD Prevention.2016. Available from:http:\/\/www.thaiheart.org\/images\/2016%20RCPT%20Guideline%20on%20Pharmacological%20Management%20of%20Dyslipidemia.pdf(accessed 10 October 2017). (in Thai)."},{"key":"e_1_2_13_43_1","first-page":"7","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: Part 1","volume":"64","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.15792"},{"key":"e_1_2_13_45_1","unstructured":"Asian\u2013Pacific Type 2 Diabetes Policy Group.Type 2 Diabetes. Practical Targets and Treatments. 3rd edn.2002. Available from:http:\/\/www2.wpro.who.int\/wpdd\/downloads\/Diabetes_Book.pdf(accessed 16 August 2017)."},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13014"},{"key":"e_1_2_13_47_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47102\/annals-acadmedsg.V44N5p164","article-title":"Prevalence of chronic kidney disease in adults with type 2 diabetes mellitus","volume":"44","author":"Low SK","year":"2015","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw069"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2016.01.002"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.01.2722"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.09.033"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12074"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2012.722"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2013.09.006"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.03.022"},{"key":"e_1_2_13_56_1","first-page":"633","article-title":"Asian chronic kidney disease best practice recommendations: Positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI)","volume":"16","author":"Li PK\u2010T","year":"2011","journal-title":"Nephrol Ther"},{"key":"e_1_2_13_57_1","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810177"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09121010"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.02.002"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30156-5"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70246-3"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04371206"},{"key":"e_1_2_13_65_1","first-page":"15","article-title":"Current perspectives on rosuvastatin","volume":"6","author":"Hu M","year":"2013","journal-title":"Integr Blood Press Control"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50140"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12296"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-9-77"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.02.006"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04139.x"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181f28fb5"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12214"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.013"},{"key":"e_1_2_13_74_1","unstructured":"Health Science Authority.Rosuvastatin (Crestor\u00ae) \u2013 New Prescribing Information [by AstraZenca]. Available from:http:\/\/www.hsa.gov.sg\/content\/hsa\/en\/Health_Products_Regulation\/Safety_Information_and_Product_Recalls\/Dear_Healthcare_Professional_Letters\/2004\/Rosuvastatin_Crestor__new_prescribing_information_by_AstraZencabr_.html#(accessed 10 August 2017)."},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2017.32.2.274"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.01.2620"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1753-0407.12610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.12610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:24:02Z","timestamp":1695500642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.12610"}},"subtitle":["\u5bf9\u4e9a\u6d322\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u7279\u522b\u662f\u6709\u80be\u529f\u80fd\u969c\u788d\u60a3\u8005\u7684\u8840\u8102\u7ba1\u7406\u7684\u5730\u533a\u5b9e\u8bc1\u548c\u56fd\u9645\u5efa\u8bae"],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/1753-0407.12610"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.12610","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]},"assertion":[{"value":"2017-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}